Dendreon Corporation
http://www.dendreon.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dendreon Corporation
Deal Watch: Japan’s SNBL To Re-Absorb US Spinout Satsuma
Shin Nippon Biomedical Laboratories would take over migraine candidate STS101, now under FDA review. Blue Water Vaccines to pick up BPH drug from Veru.
Could Moderna/Merck Cancer Vaccine Succeed Where Others Have Flopped?
The partners unveiled long-awaited proof-of-concept data for mRNA-4157 at the AACR meeting showing a statistically significant improvement in recurrence-free survival among melanoma patients.
Stock Watch: Full Approval And Surrogates Await Clinical Validation
When surrogate endpoints are used for accelerated approvals in advance of more compelling functional outcomes, how long should the duration of the confirmatory studies be?
Generation Bio’s LNP DNA-Delivery Platform Gets Big Boost From Moderna
The company aims to deliver DNA via lipid nanoparticles as well as delivering LNPs systemically to tissues beyond the liver and spleen, which the CEO called a “frontier” in an interview.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Corvas
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice